Replies to post #513749 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

PFS was the primary endpoint that DCVax-L failed to meet.

Using old endpoints and bad science. OS is the gold standard and what NWBO swapped to for their primary endpoint. Hard to argue with beating hearts. This narrative is nonsense and I didn't read past the bullshit in the first sentence.

[biosectinvestor]

You confuse surrogate endpoints and real endpoints. PFS is a surrogate for survival. When you actually price survival, the issues you try to suggest are doing involved, such falsely implied positive results, are not an issue. Beating hearts for a largely fatal disease is a real outcome, not some falsely associated outcome with survival, but actual survival.

You keep posting nonsense hour after hour, day after day, in social media. Interesting preoccupation or occupation you’ve got there.

[LearningEveryTrade]

OS using ECA is NOT confounded.
Hypothetically this could have happened....

NWBO to FDA " hey there buddy, know body knew about this at the time, but we and others discovered psuedo-progression. It shows immune system is attacking the cancer, but some placebo patients crossed over to save their life.

FDA: oh, can you just start a new trial ?

NWBO: Nah, we don't have the money, we're just a clinical stage company.

FDA: How about using control patients from other external trials... the patient data should be almost identical??

NWBO: Wow, that would be great.

[Roman516]

PFS object based on 2018 publication was the statistical objective while the OS was the final real data results, and that is the bottom line. Move on!